The human multidrug resistance protein (MRP1) causes drug resistance by extruding drugs from tumor cells. In addition to an MDR-like core, MRP1 contains an N-terminal membrane-bound region (TMD 0 ) connected to the core by a cytoplasmic linker (L 0 ). We have studied truncated MRP1 versions containing either the MDRlike core alone or the core plus linker L 0 , produced in the baculovirus-insect (Sf9) cell system. Their function was examined in isolated membrane vesicles. Fulllength MRP1 showed ATP-dependent, vanadate-sensitive accumulation of leukotriene C 4 and N-ethylmaleimide glutathione. In addition, leukotriene C 4 -stimulated, vanadate-dependent nucleotide occlusion was detected. The MDR-like core was virtually inactive. Co-expression of the core with the N-terminal region including L 0 fully restored MRP1 function. Unexpectedly, a truncated MRP1 mutant lacking the entire TMD 0 region but still containing L 0 behaved like wild-type MRP1 in vesicle uptake and nucleotide trapping experiments. We also expressed the MRP1 constructs in polarized canine kidney derived MDCKII cells. Like wild-type MRP1, the MRP1 protein without the TMD 0 region was routed to the lateral plasma membrane and transported dinitrophenyl glutathione and daunorubicin. The TMD 0 L 0 and the MRP1 minus TMD 0 L 0 remained in an intracellular compartment. Taken together, these experiments strongly suggest that the TMD 0 region is neither required for the transport function of MRP1 nor for its proper routing to the plasma membrane.
MDR1 P-glycoprotein (MDR1 Pgp) 1 and MRP1 (multidrug resistance protein 1) are members of the ATP binding cassette (ABC) transporter family that can cause multiple drug resistance in tumor cells. MDR1 Pgp is an ATP-dependent drug extrusion pump and confers resistance to a wide variety of hydrophobic toxic agents (1) . MRP1 has been shown to be a high affinity primary active transporter for the glutathioneconjugated eicosanoid, leukotriene C 4 (LTC 4 ) (2, 3) and to transport various other compounds that are conjugated to glutathione, sulfate, or glucuronide (2, 4 -6) . The physiological functions of MRP1 range from the mediation of an inflammatory response to the elimination of certain xenobiotics (7) (8) (9) (10) (11) , and this protein may play a role in the chemotherapy resistance of several types of cancer (12) .
Vanadate inhibits ATP-dependent drug transport both by MDR1 and MRP1 (1, 7) , and in the presence of vanadate, the trapping of an adenine nucleotide in these proteins has been demonstrated (13, 14) . Transported compounds specifically increase the rate of vanadate-dependent nucleotide occlusion in MRP1 (14) , similarly to what has been shown for hydrophobic drugs in the case of MDR1 Pgp (15) . Vanadate-dependent, drug-stimulated nucleotide trapping reflects a partial reaction of the multidrug transporters and thus can be used to examine their functional characteristics.
MDR1 Pgp and MRP1 share a similar core structure, consisting of a tandem repeat of transmembrane domains (TMDs) and cytoplasmic ABC-containing regions. However, MRP1 and several homologues form a subfamily of ABC transporters, characterized by a triple membrane-bound domain structure (16 -18) . These include an MDR-like core region containing two ABC units and two membrane-bound domains (TMD 1 and TMD 2 ) and an N-terminal polypeptide region of about 280 amino acids, forming a membrane-bound domain and a cytoplasmic loop (TMD 0 and L 0 ; see Fig. 1 ).
Limited proteolysis, glycosylation, and epitope insertion experiments with MRP1 indicate that the TMD 0 domain of MRP1 contains five transmembrane helices and that the N terminus of the protein is extracytosolic (17, 19, 20) . This seems to be a specific common feature of members in the MRP subfamily (16) , suggesting that these proteins evolved from a common ancestral gene. Covalent linkage of the individual domains of ABC transporters may not be essential for function, as has been demonstrated by proteolytic cleavage or separate expression of N-terminal and C-terminal halves (21, 22) .
Intact MRP1 has been expressed in baculovirus-infected insect cells (17, 21, 23) , and although the protein in this system is underglycosylated, its basic structural and transport characteristics are identical to those seen in mammalian cells (21) .
MRP1 mutants expressed in insect cells without the N-terminal TMD 0 and L 0 linker region were nonfunctional, whereas co-expression of the N-terminal TMD 0 L 0 region with the Cterminal core reconstituted a functional LTC 4 transporter (23) .
To further examine the role of the N-terminal regions in the function of MRP1, we have constructed the genetically engineered MRP1 variants shown in Fig. 1 . Constructs were expressed in baculovirus-infected insect cells and in polarized Madin-Darby canine kidney (MDCKII) cells. We show here that the TMD 0 is neither required for function of MRP1 nor for routing the protein to the basolateral plasma membrane in polarized mammalian cells.
EXPERIMENTAL PROCEDURES

Generation of MRP1 Variants and Their Expression in Insect Cells-
MRP1 cDNA was removed from modified pJ3⍀-MRP (17, 24) by digestion with SalI-NotI and subcloned into the XhoI-NotI sites of pAcSG2 plasmid (Invitrogen), yielding pAcSG2MRP. LinkerI (GATCT-GCTAGCTTAACTAGTCCGGCATGGCA) was inserted into the unique BamHI site of pAcSG2MRP (at nucleotide 840 in the MRP1 cDNA). To generate the TMD 0 L 0 construct (encoding amino acids 1-281 ϩ LLA ϩ stop), pAcSG2MRPlinkerI was digested with SpeI within the linker and with XbaI at position Ϫ5. The fragment was subcloned into pVL1393 baculovirus transfer vector (Invitrogen). To generate ⌬MRP (encoding amino acids MA ϩ 281-1531), the SpeI-NotI fragment was removed from pAcSG2MRPlinkerI and subcloned into pVL1393. To obtain the TMD 0 (encoding amino acids 1-203 ϩ LG ϩ stop) and L 0 ⌬MRP (amino acids MAL ϩ 204 -1531) constructs, the SalI-BamHI fragment was removed from the original pJ3⍀-MRP and subcloned into M13mp18, yielding M13SBMRP. A new XbaI site was introduced by site-directed mutagenesis at position 606, then the LinkerII (CTAGGCTAGCCG-GCATGGCA), including a stop codon, an NheI site, and a Kozak sequence, was inserted into the generated XbaI site. A DraIII-BamHI fragment (nucleotides 87-840) was removed from the pAcSG2MRP and substituted with the DraIII-BamHI insert of M13SBMRP containing linkerII, yielding pAcSG2MRPlinkerII. The NheI-NotI fragment of this construct was subcloned into pVL1393 to generate L 0 ⌬MRP; the XbaINheI fragment (nucleotides Ϫ5-619) was subcloned into pVL1393 to obtain TMD 0. Recombinant baculoviruses were generated by using the BaculoGold transfection kit (PharMingene). Culturing and infection of Sf9 cells and the preparation and storage of membranes was as described (25) .
Expression of MRP1 Variants in Kidney Cells-For expression of MRP1 variants in kidney-derived MDCKII cells, all cDNAs were inserted as blunt-end fragments into the retroviral vector pCMV-neo as described (26) . MRP1 was removed from pJ3⍀-MRP1 as a SalI-NotI fragment, TMD 0 L 0 as a XbaI-SpeI fragment from pAcSG2MRPlinkerI, L 0 ⌬MRP as a NheI-NotI fragment from pAcSG2MRPlinkerII, and ⌬MRP as a SpeI-NotI fragment from pAcSG2MRPlinkerI. Retroviral transductions and identification of clones expressing the different constructs were as described (26) .
Tracer protein) were incubated in the presence of 4 mM ATP or AMP in 500 l of transport buffer (10 mM MgCl 2 , 40 mM MOPS-Tris, pH 7.0, 50 mM KCl) at 23°C (LTC 4 ) or at 37°C (NEM-GS). 100-l aliquots of this suspension were added to 1 ml of ice-cold transport buffer at the time points indicated and subsequently filtered rapidly through nitrocellulose membranes (0.25-m pore size). The filters were washed twice with 5 ml of cold transport buffer, and filter-bound radioactivity was measured in scintillation fluid (Optifluor, Packard). ATPdependent transport was calculated by subtracting the activity values obtained with AMP from those in the presence of ATP. ATP-dependent 45 Ca uptake was measured by rapid filtration of the vesicles, as in Ref. 27 . Vanadate-dependent nucleotide trapping was measured basically as described (15) .
Immunochemistry-For immunofluorescence experiments, cells were grown on microporous polycarbonate filters (3-m pore size, 24.5-mm diameter, Transwell TM 3414; Costar Corp., Cambridge, MA) at a density of 2 ϫ 10 6 cells/well or on microscope slides for 3 days. No difference was observed between the two procedures. Subsequent antibody incubations and examination of the cells were as described before (28). Immunoblotting and detection of human MRP1 with monoclonal antibodies (mAbs) MRPr1 and MRPm6 were performed as described (29) . 
TABLE I Effects of various compounds on ATP-dependent LTC 4 and NEM-GS uptake in Sf9 cell membrane vesicles containing MRP1 and its truncated
versions Sf9 membrane vesicles were incubated with 3 nM LTC 4 at 23°C for 30 s or with 5 M NEM-GS at 37°C for 3 min. Tracer uptake was measured by rapid filtration, and the respective transport rates were expressed as percent of the tracer uptake measured in the absence of inhibitors. The values in this table represent means of triplicate determinations. Comparison of the amino acid sequences of the N-terminal regions among the members of the MRP subfamily showed a relatively low level of identity (16) but revealed a relatively strongly conserved peptide segment in the N-terminal part of the cytoplasmic linker region (see also Ref. 18) . Thus L 0 ⌬MRP was designed to contain an N terminus with the uninterrupted form of this conserved segment. The complementing N-terminal peptides of both truncated MRP1 versions were also generated: TMD 0 L 0 (amino acids 1-281) contains the membranebound domain and the major part of the connecting cytoplasmic region, whereas TMD 0 (amino acids 1-203) contains only the transmembrane domain (Fig. 1) .
RESULTS
Generation of Sf9 Cells Expressing MRP1 Constructs-To
The full-length human MRP1 and its truncated versions were expressed in baculovirus-infected Sf9 cells, and the amounts of the proteins produced were studied in isolated membrane preparations. Fig. 2 demonstrates the immunoblot detection of the MRP1 variants by two mAbs: MRPr1 and MRPm6. The epitope for MRPr1 has recently been mapped to amino acids 238 -247 (30), whereas MRPm6 recognizes amino acids 1511-1520 (30) . As shown in Fig. 2 , mAb MRPr1 recognizes full-length MRP1, L 0 ⌬MRP, and TMD 0 L 0 , whereas ⌬MRP is not detected by this antibody. MRPm6, as expected, reacts with MRP1, ⌬MRP, and L 0 ⌬MRP but not with TMD 0 L 0 . Because we have no relevant antibody for the detection of TMD 0 , we did not use this construct in the present experiments.
As shown before (17, 21) , human MRP1 in Sf9 cells is made in an underglycosylated form, with an apparent M r of 150 kDa. According to the immunoblots, the amount of MRP1 in Sf9 cell membranes was about five times higher than in a membrane preparation isolated from the highly drug-resistant HL60-MRP1 cell line. The expression level of the various truncated constructs was similar to that of MRP1. When the complementing peptides were co-expressed by virus co-infection, care was taken to use baculovirus ratios that produced a maximum level of co-expression for both the core and N-terminal regions (we found that a higher titer of the viruses directing the expression of the smaller N-terminal regions suppressed the expression of the core). The data shown in Fig. 2 indicate that all the MRP1 variants were efficiently produced in the Sf9 cells. Slight variations in the expression levels of these variants between various membrane preparations were still observed. The transport data were therefore corrected for the protein levels (see below).
Uptake of NEM-GS and LTC 4 into Sf9-derived Vesicles-In the following experiments we have examined the function of MRP1 and its truncated versions by measuring the transport of the established MRP1 substrates, LTC 4 and NEM-GS (see 2, 3, 7). To determine the transport function of the various MRP1 constructs, we estimated the relative amount of transportcompetent inside-out vesicles in the Sf9 membrane preparations. For this purpose, we measured the rate of endogenous ATP-dependent calcium uptake in each preparation, which was found to be between 0.5-1.5 nmol mg Ϫ1 min Ϫ1 . In all further experiments the LTC 4 and NEM-GS transport rates were corrected for the mean relative vesicle contents. When comparing the transport rates by the truncated MRP1 constructs, we also corrected these rates by their relative expression levels, as determined by immunoblotting. Fig. 3 (panels A and B) demonstrate the time course of tritiated LTC 4 (50 nM) and NEM-GS (50 M) uptake in Sf9 membrane vesicles containing human MRP1 variants or ␤-galactosidase. As shown, full-length MRP1 gave an ATP-dependent increase in vesicular accumulation of radioactivity that was linear for LTC 4 for about 30 s at 23°C and for NEM-GS for about 3 min at 37°C. The initial rate of ATP-dependent LTC 4 transport in MRP1-containing membranes was about 50 pmol mg Ϫ1 min Ϫ1 , whereas that of the NEM-GS transport was about 160 pmol mg Ϫ1 min Ϫ1 under these conditions. Rapid washing of the vesicles with cold substrate-containing solutions did not alter the vesicular LTC 4 and NEM-GS levels, whereas the addition of concentrated sucrose (final concentration 1 M) or low concentrations of Triton X-100 (0.02%) to the media eliminated ATP-dependent tracer accumulation.
As shown in Table I , LTC 4 uptake by MRP1-containing membrane vesicles was strongly inhibited by NEM-GS and NEM-GS uptake by LTC 4 , whereas the uptake of both compounds was abolished by sodium orthovanadate, oxidized glutathione (GSSG), or sulfinpyrazone (an inhibitor of organic anion transporters (7, 28) ). A partial inhibition of LTC 4 and NEM-GS uptake was observed by calcein-AM and a high concentration of vinblastine, whereas 5-fluorouracil had no inhibitory effect.
The TMD 0 L 0 part of MRP1 did not evoke any additional transport activity compared with that seen in the control, ␤-galactosidase-containing vesicles. Vesicles containing ⌬MRP showed an LTC 4 and NEM-GS uptake of about 10% that of wild-type MRP1 (5 and 12 pmol mg Ϫ1 min Ϫ1 , respectively). Interestingly, the co-expression of ⌬MRP and TMD 0 L 0 resulted in somewhat higher uptake rates for LTC 4 and NEM-GS (initial rates of about 60 and 210 pmol mg Ϫ1 min Ϫ1 , respectively) than those catalyzed by intact MRP1. L 0 ⌬MRP was found to induce a high level ATP-dependent transport activity for both substrates, with initial rates of about 35 pmol of LTC 4 mg Ϫ1 min Ϫ1 and 70 pmol of NEM-GS mg Ϫ1 min Ϫ1 . In all cases vesicular tracer uptake was eliminated by the addition of 0.02% Triton X-100 or 1 M sucrose.
As shown in Table I , LTC 4 and NEM-GS uptake in mem- 4 Transport by Sf9-derived Vesicles-The concentration dependence of the ATP-dependent LTC 4 and NEM-GS transport was examined for all MRP1 variants. The double-reciprocal plots of these data are shown in Fig. 3 (panels C and D) , and the results are summarized in Table II . In accordance with published data (4), the MRP1 K m value for ATP-dependent LTC 4 transport was about 135 Ϯ 35 nM, whereas that for NEM-GS was about 155 Ϯ 40 M. Co-expression of ⌬MRP and TMD 0 L 0 resulted in similar K m values and somewhat higher V max values for the ATP-dependent uptake of LTC 4 and NEM-GS than those measured for full-length MRP1 (Table II) .
As indicated in Fig. 3 and Table II , the K m and V max values for LTC 4 transport were only slightly different in membranes containing L 0 ⌬MRP than in membranes containing MRP1. Differences were within the range of experimental error. In the case of NEM-GS uptake by L 0 ⌬MRP, the V max was again similar, but the K m value was significantly higher (2.5-fold) than for full-length MRP1. These results indicate that the TMD 0 region is not required for MRP1-mediated LTC 4 or NEM-GS transport.
Vanadate Trapping by MRP1 Variants-Vanadate-dependent nucleotide trapping of MRP1 reflects a partial reaction of the ATPase cycle of this protein, stimulated by the transported substrates (13-15). By using magnesium-8-azido- [ 32 P]ATP a covalent photoaffinity labeling of the MRP1 variants could also be achieved. Fig. 4 shows the nucleotide trapping by MRP1, which was 2-3-fold stimulated by 600 nM LTC 4 and fully inhibitable by pretreatment with 1 mM N-ethylmaleimide. Vanadate-dependent nucleotide trapping by MRP1 was also stimulated by 1 mM NEM-GS (data not shown). In control membranes containing ␤-galactosidase, the low level background labeling of some endogenous proteins was not influenced by any of the MRP1 substrates (data not shown).
In contrast, ⌬MRP did not measurably trap nucleotide either in the presence or absence of LTC 4 , even if longer incubation periods (20 min) were applied. However, co-expression of ⌬MRP with TMD 0 L 0 resulted in NEM-sensitive, LTC 4 -stimulated nucleotide trapping in the protein band representing ⌬MRP. Also, in membranes containing L 0 ⌬MRP, clear NEMinhibitable nucleotide trapping was detected in the relevant protein band, and the addition of LTC 4 significantly increased the amount of trapping by this MRP1 mutant (Fig. 4) .
Generation of MDCKII Cells Expressing MRP1 Mutants-We have previously shown that MDCKII cells stably expressing human MRP1 can be generated by transducing these cells with a retroviral construct containing MRP1 cDNA (26, 31) . Using the same procedure, we generated MDCKII cells stably expressing ⌬MRP, TMD 0 L 0 , and L 0 ⌬MRP. By Western blot analysis of crude cell extracts, using the same antibodies as in Fig.  2 , we identified several clones that produced substantial amounts of the MRP1 variants (Fig. 5, A and B) . At the exposure time shown, no signal was detectable with mAb MRPm6 and MRPr1 in wild-type MDCKII cells. The TMD 0 L 0 protein appeared as a smear around 49 kDa in these cells. As two of the functional MRP1 glycosylation sites are present in this fragment (19) , this might be explained by partial glycosylation of this protein and/or partial degradation.
Immunolocalization of MRP1 Deletion Mutants in MDCKII Cells-Intact MRP1 is localized in the lateral plasma membrane in polarized LLC-PK1 and MDCKII cells (28, 31) . The subcellular localization of the MRP1 mutants was determined by indirect immunofluorescence using confocal laser scanning microscopy in cells growing in a monolayer. The wild-type MRP1, TMD 0 L 0 , and L 0 ⌬MRP proteins were detected with mAb MRPr1, and the ⌬MRP protein was detected with mAb MRPm6. Localization was examined at the horizontal plane and at the plane perpendicular to the monolayer (Fig. 6) . The results can be summarized as follows. (i) Some of the L 0 ⌬MRP protein was detected intracellularly, but a substantial amount was present in the lateral membranes, (ii) the TMD 0 L 0 protein was present in large intracellular vesicles, and (iii) the ⌬MRP protein was present in a relatively low concentration and was detected intracellularly. In some cells a concentration of signal was detected at the position of the lateral membrane, but this was only seen in a small fraction of the cells analyzed.
Transport of Dinitrophenyl Glutathione by MDCKII-derived Clones-We have shown before that the transport activity of MRP1 can be studied in polarized cells using 1-chloro-2,4-dinitro[
14 C]benzene (28) . This hydrophobic compound rapidly diffuses over membranes and is conjugated intracellularly to GSH by glutathione S-transferases. The resulting hydrophilic [ 14 C]DNP-GS can only leave the cell by carrier-mediated transport. Transport across the apical and basolateral plasma membrane can be distinguished by growing cells as a monolayer on a porous membrane. The [
14 C]DNP-GS transport by polarized monolayers of the various MDCKII-derived clones is presented in Fig. 7 . The MDCKII-TMD 0 L 0 cells were not tested in transport assays as they lack the ABC domains that are required for transport activity. (28) . These experiments could not simply be repeated with MDCKII cells, as these cells contain relatively high amounts of canine drug-transporting Pgp, resulting in high backgrounds in daunorubicin transport experiments. Fortunately, this background can be suppressed by low concentrations (0.1 M) of the Pgp inhibitor PSC833, which have no significant effect on cMOAT (MRP2) in MDCKII-cMOAT cells (26) . These conditions were also used to study the vectorial transport of daunorubicin by the MRP1 mutants. [ 3 H]Daunorubicin was added either to the apical or to the basolateral side of a cell monolayer, and the accumulation of radioactivity in the opposite compartment was followed. Transport of [ 3 H]daunorubicin in wild-type MDCKII cells was virtually blocked at the concentration of PSC833 used in the experiment. Relative to wild-type cells, the MDCKII-MRP and MDCKII-L 0 ⌬MRP cells showed an increased basolateral transport activity (Fig. 8, left  panels) . No significant transport was observed in the MDCKII-⌬MRP cells (data not shown). As a control for an apical transporter, we used MDCKII cells retrovirally transduced with human MDR1 cDNA. These cells contain a relatively high concentration of MDR1 Pgp in their apical plasma membrane that is only partially inhibited by the low concentration of PSC833 used in these experiments (see Fig. 5C ). 2 As expected these cells transported daunorubicin at high rate toward the apical side of the monolayer.
Sulfinpyrazone inhibits MRP1 in intact pig kidney cells (28) and in Sf9-derived vesicles (Table I) . Fig. 8 (right panels) shows that 1 mM sulfinpyrazone also blocks transport to the basolateral side in MDCKII-MRP and MDCKII-L 0 ⌬MRP cells, whereas transport in MDCKII-MDR1 cells was not affected. As a control, a high concentration of PSC833 (5 M) was used. This concentration blocked daunorubicin transport in the MDCKII-2 R. Evers and P. Borst, unpublished data. MDR1 cells. As high concentrations of PSC833 are known to inhibit MRP1 (2), also some inhibition of transport in MDCKII-MRP and MDCKII-L 0 ⌬MRP was observed (Fig. 8, middle  panels) . DISCUSSION Our results suggest that the cytoplasmic L 0 linker of MRP1 (amino acids 204 -281) forms a functional domain that is essential and sufficient for promoting substrate transport. In contrast, the N-terminal putative membrane-bound TMD 0 (amino acids 1-203) region is neither required for transport of organic anions and of daunorubicin, as shown in Sf9 and mammalian cells, nor is it required for directing the protein toward the lateral plasma membrane in polarized MDCKII cells. Both the glutathione conjugate transport and the vanadate-dependent nucleotide trapping experiments suggest that the MDRlike core of MRP1 in Sf9 cells is virtually inactive as a transporter. Still, by interacting with the complementing N-terminal region, the core regains full transport activity, confirming and extending the results of Gao et al. (23) .
Gao et al. (23) found that removal of the whole TMD 0 domain or only its first N-terminal transmembrane helix abolished MRP1 function. This led these authors to conclude that the entire TMD 0 L 0 region is essential for transport activity. In contrast, our results show that the L 0 ⌬MRP protein is fully functional and also properly routed to the lateral membrane of polarized mammalian cells. A possible explanation for this discrepancy is that the L 0 ⌬MRP construct we generated encodes a protein that is 25 amino acids longer at its N terminus than the construct used by Gao et al. (23) . This region encompasses a stretch of amino acids that is conserved among the members of the MRP family (18) and that could be essential for MRP1 substrate recognition or for the integrity of the L 0 segment as a functional domain. It is not obvious why the construct of Gao et al. (23) lacking only the first N-terminal transmembrane segment of TMD 0 was also inactive. It seems possible, however, that the deletion of the first N-terminal transmembrane segment disturbs the structure of other neighboring membrane-associated regions and that this results in an inactive transporter molecule.
The N-terminal TMD 0 region is found in the human MRP family members MRP1, cMOAT (MRP2), MRP3, and MRP6, 3 and although this region shows a low overall amino acid identity among these proteins, it is structurally conserved in evolution (16) . It is therefore hard to believe that it would not be essential. Obviously, we cannot exclude that it plays a subtle role in the function of MRP1 that we missed in the experiments done thus far. For instance, the TMD 0 region could (i) have a regulatory role in the functional interaction of MRP1 with other membrane proteins, (ii) contribute to proper protein routing in other cells than kidney, (iii) be required for stabilization of the L 0 region, and/or (iv) be important for the efficient transport of some substrates. This latter possibility derives some support from the higher K m value for NEM-GS obtained for L 0 ⌬MRP than for wild-type MRP1 (Table II) . A more detailed analysis will be required to define such a role for this domain.
The routing signals that determine the lateral plasma membrane localization of MRP1 are not known yet. Our results clearly show, however, that the TMD 0 region is not required, at least in kidney. We are currently testing the possibility that the L 0 domain contains a dominant basolateral routing signal by fusing this domain to ABC transporters that are normally routed to the apical plasma membrane. Because the drug extrusion activity of MRP1 has a major role in the chemotherapy resistance of human tumors, the current demonstration of the function of the N-terminal cytoplasmic L 0 domain may significantly help the design of efficient modulators or inhibitors for this clinically important protein.
